# Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

> **NCT01025089** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Thymoma
- Thymic Carcinoma
- Clinical Masaoka Stage II to IVA

## Interventions

- **DRUG:** Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

## Key facts

- **NCT ID:** NCT01025089
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025089, "Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01025089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*